A few case reports from China and Italy, along with a Chinese meta-analysis, have shown diabetes to be an important risk factor for severe disease requiring ventilation [18]. Further, a study had shown a direct metabolic link between SARS-CoV and diabetes, postulating that the virus enters the pancreatic islets which express ACE2, leading to acute β-cell damage and transient Type 2 diabetes mellitus (T2DM) [19]. Evidence from an animal study points toward increased ACE2 activity in pancreas of persons with diabetes besides its elevated expression in other tissues such as lung, liver and heart [20]. Hence, optimal control of T2DM, for both chronic and transient cases, might help in the treatment of COVID-19. Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same. Considering its pleiotropic effects and a possible role in combating hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV) through increasing insulin sensitivity [23], metformin can be a real game-changer for treating this pandemic.